Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy.

MLA

Musoro, J. Z., et al. “Minimally Important Differences for Interpreting the EORTC QLQ‐C30 in Patients with Advanced Colorectal Cancer Treated with Chemotherapy.” Colorectal Disease, vol. 22, no. 12, Dec. 2020, pp. 2278–87. EBSCOhost, https://doi.org/10.1111/codi.15295.

APA

Musoro, J. Z., Sodergren, S. C., Coens, C., Pochesci, A., Terada, M., King, M. T., Sprangers, M. A. G., Groenvold, M., Cocks, K., Velikova, G., Flechtner, H. ‐H., & Bottomley, A. (2020). Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy. Colorectal Disease, 22(12), 2278–2287. https://doi.org/10.1111/codi.15295

Chicago

Musoro, J. Z., S. C. Sodergren, C. Coens, A. Pochesci, M. Terada, M. T. King, M. A. G. Sprangers, et al. 2020. “Minimally Important Differences for Interpreting the EORTC QLQ‐C30 in Patients with Advanced Colorectal Cancer Treated with Chemotherapy.” Colorectal Disease 22 (12): 2278–87. doi:10.1111/codi.15295.